CHMP recommends label update for Esbriet in idiopathic pulmonary fibrosis
Approved in the EU in 2011, Esbriet is indicated for the treatment of adults with mild to moderate IPF. The CHMP recommendation includes data from the phase III
Pacira BioSciences has entered into an exclusive agreement with Italian pharmaceutical company Molteni Farmaceutici to distribute and commercialise Exparel across the EU and the UK.
As previously announced, Islet Sciences and BHV have entered into a merger agreement that will combine the operations and development pipelines of the two companies. Upon closing of
The allowed claims cover inhibitors of PRMT5 and methods of cancer treatment with PRMT5 inhibitors. PRMT5 is implicated in several cancers, including blood cancers. Epizyme also announced the